Use of the combination therapy requires detection of the patient’s status by an FDA-approved test, following progression on or after an endocrine-based regimen.
Read More
Adoption of the technology is based on the premise that healthcare providers need to get the right bag of blood products to the right patient at the right time.
Read More
Beckman’s Early Sepsis Indicator is a first-of-its-kind, hematology-based cellular biomarker for identifying patients with sepsis, or those at increased risk of developing sepsis.
Read More
With an increasing US prevalence of vector-borne illnesses such as Lyme disease, there is a pressing need to improve clinical diagnostics.
Read More
BD’s quality control media for platelet testing have been CE marked and cleared by FDA.
Read More